Protein Summary
Developmentally regulated, secreted growth factor homologous to pleiotrophin (PTN), which has heparin binding activity. Binds anaplastic lymphoma kinase (ALK) which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate (IRS1), followed by the activation of mitogen-activated protein kinase (MAPK) and PI3-kinase, and the induction of cell proliferation. Involved in neointima formation after arterial injury, possibly by mediating leukocyte recruitment. Also involved in early fetal adrenal gland development (By similarity). This gene encodes a member of a small family of secreted growth factors that binds heparin and responds to retinoic acid. The encoded protein promotes cell growth, migration, and angiogenesis, in particular during tumorigenesis. This gene has been targeted as a therapeutic for a variety of different disorders. Alternatively spliced transcript variants encoding multiple isoforms have been observed. [provided by RefSeq, Jul 2012]
- ENST00000359803
- ENSP00000352852
- ENSG00000110492
- ENST00000395565
- ENSP00000378932
- ENST00000395566
- ENSP00000378933
- ENST00000395569
- ENSP00000378936
- ENST00000405308
- ENSP00000385451
- ENST00000407067
- ENSP00000384034
- MK1
- NEGF2
- MK
- ARAP
- NEGF2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.9 | ||
PubMedID | 0.84 | ||
biological term | 0.82 | ||
transcription factor | 0.78 | ||
biological process | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 842.84 (req: < 5)
Gene RIFs: 159 (req: <= 3)
Antibodies: 529 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 842.84 (req: >= 5)
Gene RIFs: 159 (req: > 3)
Antibodies: 529 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 21
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 7
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0